Last reviewed · How we verify

Proactive TDM-based dosing of guselkumab

University Hospital, Ghent · FDA-approved active Small molecule Quality 5/100

Proactive TDM-based dosing of guselkumab is a Small molecule drug developed by University Hospital, Ghent. It is currently FDA-approved. Also known as: Tremfya.

At a glance

Generic nameProactive TDM-based dosing of guselkumab
Also known asTremfya
SponsorUniversity Hospital, Ghent
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Proactive TDM-based dosing of guselkumab

What is Proactive TDM-based dosing of guselkumab?

Proactive TDM-based dosing of guselkumab is a Small molecule drug developed by University Hospital, Ghent.

Who makes Proactive TDM-based dosing of guselkumab?

Proactive TDM-based dosing of guselkumab is developed and marketed by University Hospital, Ghent (see full University Hospital, Ghent pipeline at /company/university-hospital-ghent).

Is Proactive TDM-based dosing of guselkumab also known as anything else?

Proactive TDM-based dosing of guselkumab is also known as Tremfya.

What development phase is Proactive TDM-based dosing of guselkumab in?

Proactive TDM-based dosing of guselkumab is FDA-approved (marketed).

Related